Effect of Hydroxyethyl Starch 130/0.4 on Blood Loss and Coagulation in Patients With Recent Exposure to Dual Antiplatelet Therapy Undergoing Off-Pump Coronary Artery Bypass Graft Surgery
Open Access
- 1 January 2011
- journal article
- research article
- Published by Japanese Circulation Society in Circulation Journal
- Vol. 75 (10) , 2397-2402
Abstract
Background: Hydroxyethyl starch (HES) solutions are often used for maintaining intravascular volume and improving microperfusion, while a large amount of HES can cause adverse effects on coagulation. As the indications for clopidogrel expand, an increasing number of patients undergoing off-pump coronary artery bypass surgery (OPCAB) are also undergoing dual antiplatelet therapy (DAPT), with its higher risk of bleeding complications. The aim of the present study was to determine whether a moderate dose of 6% HES 130/0.4 significantly increases perioperative blood loss in patients with continued DAPT within 5 days of OPCAB. Methods and Results: Patients who received clopidogrel and aspirin within 5 days of OPCAB were randomly allocated to receive HES 130/0.4 (≤30ml/kg) followed by crystalloid infusion (HES group, n=53), or crystalloid only (crystalloid group, n=53) perioperatively. The amount of perioperative blood loss (sum of bleeding during the intraoperative and postoperative 24-h period), transfusion requirements, modified thromboelastography and coagulation variables, hemodynamic parameters, and fluid balance were recorded. Perioperative blood loss and coagulation profiles were similar between the groups, but the postoperative hemoglobin level was higher in the crystalloid group. Conclusions: Up to 30ml·kg-1·day-1 of 6% HES 130/0.4 did not increase the perioperative blood loss compared to crystalloid in patients with recent exposure to DAPT undergoing OPCAB. HES 130/0.4 caused a similar degree and duration of coagulation impairment as observed when only crystalloid was given. (Circ J 2011; 75: 2397-2402)Keywords
This publication has 33 references indexed in Scilit:
- Guideline on antiplatelet and anticoagulation management in cardiac surgeryEuropean Journal of Cardio-Thoracic Surgery, 2008
- Effects of Continuous Administration of Clopidogrel Before Off-Pump Coronary Artery Bypass Grafting in Patients With Acute Coronary Syndrome A Propensity Score AnalysisCirculation Journal, 2007
- Emergency Coronary Artery Bypass Graft Surgery for Acute Coronary SyndromeCirculation, 2006
- Effect of Clopidogrel Premedication in Off-Pump Cardiac SurgeryCirculation, 2006
- Does Clopidogrel Increase Blood Loss Following Coronary Artery Bypass Surgery?The Annals of Thoracic Surgery, 2004
- Benefits and Risks of the Combination of Clopidogrel and Aspirin in Patients Undergoing Surgical Revascularization for Non–ST-Elevation Acute Coronary SyndromeCirculation, 2004
- Off-pump coronary artery bypass surgery: physiology and anaesthetic management †British Journal of Anaesthesia, 2004
- Effects of Aspirin Dose When Used Alone or in Combination With Clopidogrel in Patients With Acute Coronary SyndromesCirculation, 2003
- Perioperative Advantages of Off-Pump Coronary Artery Bypass Grafting.Circulation Journal, 2002
- The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme. Rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular diseaseEuropean Heart Journal, 2000